Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial‐mesenchymal transition

Zheng, Chen; Xia, Erjie; Quan, Ruida; Bhandari, Adheesh; Wang, Ouchen; Hao, Rutian

doi:10.1002/cbf.3455

Cited by 7 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SLC5A8 codes for a transporter belonging to the Na(+)/glucose co-transporter gene family, and the protein coded by SLC5A8 can transport iodide and regulate the Na(+)-coupled and electrogenic transport of many monocarboxylates ( 39 ). Our results support our earlier observations, which showed that SEMA3D ( 40 ), CRABP1 ( 41 ), SLC5A8 ( 42 ), and SCARA5 ( 43 ) are tumor suppressor genes in PTC, while GDF15 ( 44 ), CHI3L1 ( 45 , 46 ), GABRB2 ( 47 ), and ARHGAP36 ( 48 ) are oncogenic genes in PTC. However, very little research has been conducted on the roles of B3GNT3 , TMPRSS6 , CLDN16 , MFAP4 , MYOC , C7 , APOD , SLIT1 , TMEM215 , and IGSF1 in PTC.…”

Section: Discussionsupporting

confidence: 92%

Identification and validation of subclusters of papillary thyroid carcinoma based on Human Phenotype Ontology

Xuan¹,

Hu²,

Xu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

Background The increase in the diagnosis of papillary thyroid carcinoma (PTC) has prompted researchers to establish a diagnostic model and identify functional subclusters. The Human Phenotype Ontology (HPO) platform is widely available for differential diagnostics and phenotype-driven investigations based on next-generation sequence-variation data. However, a systematic and comprehensive study to identify and validate PTC subclusters based on HPO is lacking. Methods We first used the HPO platform to identify the PTC subclusters. An enrichment analysis was then conducted to examine the key biological processes and pathways associated with the subclusters, and a gene mutation analysis of the subclusters was conducted. For each subcluster, the differentially expressed genes (DEGs) were selected and validated. Finally, a single-cell RNA-sequencing data set was used to verify the DEGs. Results In our study, 489 PTC patients from The Cancer Genome Atlas (TCGA) were included. Our analysis demonstrated that distinct subclusters of PTC are associated with different survival times and have different functional enrichment, and that C-C motif chemokine ligand 21 ( CCL21 ) and zinc finger CCHC-type containing 12 ( ZCCHC12 ) were the common down- and upregulated genes, respectively, in the 4 subclusters. Additionally, 20 characteristic genes were identified in the 4 subclusters, some of which have previously been reported to have roles in PTC. Further, we found that these characteristic genes were mainly expressed in thyrocytes, endothelial cells, and fibroblasts, and were rarely expressed in immune cells. Conclusions We first identified subclusters in PTC based on HPO and found that patients with distinct subclusters have different prognoses. We then identified and validated the characteristic genes in the 4 subclusters. These findings are expected to serve as a crucial reference that will improve our understanding of PTC heterogeneity and the use of novel targets.

show abstract

Section: Discussionsupporting

confidence: 92%

Identification and validation of subclusters of papillary thyroid carcinoma based on Human Phenotype Ontology

Xuan¹,

Hu²,

Xu³

et al. 2023

Gland Surg

View full text Add to dashboard Cite

show abstract

“…SCARA5 downregulation was essential for EMT-induced migration in A549 cells and SCARA5 was a direct Snail1 target modulating cancer cell mobility during EMT 8 . SCARA5 also modulated the expression of epithelial-mesenchymal transition-related proteins in thyroid cancer 18 . These results demonstrated that SCARA5 could inhibit cell invasion and metastasis by modulating the actin cytoskeleton in cancer cell lines.…”

Section: Discussionmentioning

confidence: 94%

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression

Zhang¹,

Liu²,

Wang³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Scavenger receptor class A member 5 (SCARA5) has been reported to be implicated in several types of cancer. However, its biological roles and mechanism of SCARA5 in gastric cancer (GC) have not been elucidated. In the present study, SCARA5 expression was found to be downregulated in GC which was associated with promoter methylation. The protein level of SCARA5 was negatively associated with aggressive clinicopathological characteristics, as well as poor prognosis. Moreover, SCARA5 overexpression markedly suppressed the growth, migration and invasion of GC cell lines in vitro. Furthermore, upregulation of SCARA5 inhibited gastric tumor growth and metastasis in a xenograft model. Mechanistic analysis revealed that SCARA5 suppressed the migration and invasion of GC cells via inhibiting epithelial-mesenchymal transition (EMT) and inactivating MMP-2 and MMP-9. Taken together, these results demonstrated that SCARA5 might play vital roles in the GC genesis and progression and could serve as a potential biomarker for diagnosis and therapeutic target of GC.

show abstract

“…Meanwhile, Liu et al found that CNS5 and SPAG5 could affect hepatocellular carcinoma progression by mediating ubiquitination of β-catenin to reduce the expression of SCARA5 [ 9 , 10 ]. Moreover, Chen and Liu et al also discovered that the aberrant expression of SCARA5 in thyroid cancer and lung cancer impacts cellular invasion and migration [ 11 , 12 ]. What’s more, Li et al reported that SCARA5 could act as ferritin receptor to facilitate intracellular iron increasing and promote the kidney development [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Unlike other family members that are found primarily in macrophages, scavenger receptor protein 5 (SCARA5), located on chromosome 8p21, is widely expressed in a variety of human tissues, including bladder, ovary, kidney, and skin [7]. SCARA5 has been reported to act as a tumor suppressor in many cancers [6,[8][9][10][11][12]. For example, Huang and Ulker et al respectively reported that the expression of SCARA5 was specifically decreased in hepatocellular carcinoma and breast cancer due to promoter methylation [6,8].…”

Section: Introductionmentioning

confidence: 99%

SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain

et al. 2022

View full text Add to dashboard Cite

Background Esophageal squamous cell carcinoma (ESCC) remains one of the most lethal cancers worldwide accompany with an extremely poor prognosis. Therefore, this study aims to screen for new molecules affecting ESCC and explore their mechanisms of action to provide ideas for targeted therapies for ESCC. Methods Firstly, we screened out the membrane protein SCARA5 by high-throughput sequencing of the ESCC patient tissues, and RT-qPCR and WB were used to verify the differential expression of SCARA5 in esophageal cell lines, and IHC analyzed the expression localization of SCARA5 in ESCC tissue. Then, flow cytometry, wound healing assay, Transwell assay and CCK-8 assay were used to explore the effects of SCARA5 on cell cycle, migration and invasion as well as cell proliferation activity of esophageal squamous carcinoma cells. Meanwhile, transmission electron microscopy was used to detect changes in cellular mitochondrial morphology, and flow cytometry were used to detect changes in intracellular reactive oxygen metabolism, and immunofluorescence and flow cytometry were used to detect changes in intracellular Fe2+. Mechanistically, co-immunoprecipitation was used to detect whether SCARA5 binds to ferritin light chain, and ferroptosis-related protein expression was detected by WB. Finally, the tumor xenograft model was applied to validation the role of SCARA5 tumor growth inhibition in vivo. Results We found that SCARA5 was aberrantly decreased in ESCC tissues and cell lines. Furthermore, we confirmed that SCARA5 suppressed the cell cycle, metastasis and invasion of ESCC cells. Meanwhile, we also found that overexpression of SCARA5 caused changes in mitochondrial morphology, accumulation of intracellular reactive oxygen species and increased intracellular Fe2+ in ESCC cells, which induced ferroptosis in ESCC cells. Mechanically, we validated that SCARA5 combined with ferritin light chain and increased intracellular Fe2+. As well as, overexpression SCARA5 induced ferroptosis by increasing ferritin light chain in nude mice subcutaneous tumors and inhibited the growth of nude mice subcutaneous tumors. Conclusion Collectively, our findings demonstrated that SCARA5 suppressed the proliferation and metastasis of ESCC by triggering ferroptosis through combining with ferritin light chain.

show abstract

Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial‐mesenchymal transition

Cited by 7 publications

References 36 publications

Identification and validation of subclusters of papillary thyroid carcinoma based on Human Phenotype Ontology

Identification and validation of subclusters of papillary thyroid carcinoma based on Human Phenotype Ontology

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression

SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain

Contact Info

Product

Resources

About